Ropinirolehydrochloride , ≥99% , 91374-20-8

Synonym(s):
4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride;Ropinirole hydrochloride;SKF 101468 hydrochloride

CAS NO.：91374-20-8

Empirical Formula: C16H25ClN2O

Molecular Weight: 296.84

MDL number: MFCD01754173

EINECS: 635-615-9

PRODUCT Properties

• Melting point: 241-243°C
• storage temp.: 2-8°C
• solubility: H2O: >10mg/mL
• form: powder
• color: light yellow
• InChI: InChI=1S/C16H24N2O.ClH/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15;/h5-7H,3-4,8-12H2,1-2H3,(H,17,19);1H
• InChIKey: XDXHAEQXIBQUEZ-UHFFFAOYSA-N
• SMILES: C12CC(=O)NC=1C=CC=C2CCN(CCC)CCC.Cl

Description and Uses

ReQuip was launched in the UK as a monotherapy or in combination with low-dose levodopa for the treatment of early-stage idiopathic Parkinson's disease. An eight step (24% overall yield) synthesis from isochroman provides access to ropinirole. It is a non-ergot postsynaptic dopamine D₂ agonist with activity in the extrapyramidal system. It has weak or no significant activity at α₂-adrenergic, 5-HT₂ receptors and is inactive at 5-HT₁, benzodiazepine, GABA, α₁ and β adrenoreceptors. Thus it has essentially no CNS side effects, fewer dyskinesias and on-off fluctuations. In animals, it was able to reverse all motor deficits induced by MPTP. Tolerance is not developed and ropinirole has similar postsynaptic potency to apomorphine but with significantly less stereotyped behavior.

antiparkinsonian;non-ergoline D2, D3, and D4 dopamine receptor agonist with highest affinity for D3

Safety

• Symbol(GHS): GHS07,GHS09
• Signal word: Warning
• Hazard statements: H302-H400
• Precautionary statements: P273-P301+P312+P330
• Hazard Codes: Xn,N,Xi
• Risk Statements: 22-50/53-36/38
• Safety Statements: 36-60-61-37/39-26
• RIDADR: UN 3077 9/PG 3
• WGK Germany: 3
• RTECS: NM3288250
• HS Code: 2933790002